Difference between revisions of "HAEM5:Burkitt lymphoma"
| [unchecked revision] | [checked revision] |
Bailey.Glen (talk | contribs) |
Bailey.Glen (talk | contribs) |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Burkitt lymphoma}} | {{DISPLAYTITLE:Burkitt lymphoma}} | ||
| − | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]] | + | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] |
{{Under Construction}} | {{Under Construction}} | ||
| − | <blockquote class='blockedit'>{{Box-round|title= | + | <blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Burkitt Lymphoma]]. |
}}</blockquote> | }}</blockquote> | ||
| + | |||
| + | <span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span> | ||
| + | |||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| Line 12: | Line 15: | ||
__TOC__ | __TOC__ | ||
| − | == | + | ==WHO Classification of Disease== |
| − | Mature B-cell | + | {| class="wikitable" |
| − | + | !Structure | |
| − | + | !Disease | |
| − | + | |- | |
| − | + | |Book | |
| + | |Haematolymphoid Tumours (5th ed.) | ||
| + | |- | ||
| + | |Category | ||
| + | |B-cell lymphoid proliferations and lymphomas | ||
| + | |- | ||
| + | |Family | ||
| + | |Mature B-cell neoplasms | ||
| + | |- | ||
| + | |Type | ||
| + | |N/A | ||
| + | |- | ||
| + | |Subtype(s) | ||
| + | |Burkitt lymphoma | ||
| + | |} | ||
==Definition / Description of Disease== | ==Definition / Description of Disease== | ||
| − | Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories | + | Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories, diagnostic criteria if applicable, and differential diagnosis if applicable. Other classifications can be referenced for comparison.'') </span> |
==Synonyms / Terminology== | ==Synonyms / Terminology== | ||
| Line 34: | Line 51: | ||
==Clinical Features== | ==Clinical Features== | ||
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span> | + | Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span> |
{| class="wikitable" | {| class="wikitable" | ||
|'''Signs and Symptoms''' | |'''Signs and Symptoms''' | ||
| − | |EXAMPLE Asymptomatic (incidental finding on complete blood counts) | + | |<span class="blue-text">EXAMPLE:</span> Asymptomatic (incidental finding on complete blood counts) |
| − | EXAMPLE B-symptoms (weight loss, fever, night sweats) | + | <span class="blue-text">EXAMPLE:</span> B-symptoms (weight loss, fever, night sweats) |
| − | EXAMPLE Fatigue | + | <span class="blue-text">EXAMPLE:</span> Fatigue |
| − | EXAMPLE Lymphadenopathy (uncommon) | + | <span class="blue-text">EXAMPLE:</span> Lymphadenopathy (uncommon) |
|- | |- | ||
|'''Laboratory Findings''' | |'''Laboratory Findings''' | ||
| − | |EXAMPLE Cytopenias | + | |<span class="blue-text">EXAMPLE:</span> Cytopenias |
| − | EXAMPLE Lymphocytosis (low level) | + | <span class="blue-text">EXAMPLE:</span> Lymphocytosis (low level) |
|} | |} | ||
| Line 142: | Line 159: | ||
!Notes | !Notes | ||
|- | |- | ||
| − | |EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC) | + | |<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)||<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR||<span class="blue-text">EXAMPLE:</span> der(22)||<span class="blue-text">EXAMPLE:</span> 20% (COSMIC) |
| − | EXAMPLE 30% (add reference) | + | <span class="blue-text">EXAMPLE:</span> 30% (add reference) |
|Yes | |Yes | ||
|No | |No | ||
|Yes | |Yes | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | ||
| Line 187: | Line 204: | ||
==Individual Region Genomic Gain / Loss / LOH== | ==Individual Region Genomic Gain / Loss / LOH== | ||
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span> | + | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'') </span> |
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 197: | Line 214: | ||
!Notes | !Notes | ||
|- | |- | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
7 | 7 | ||
| − | |EXAMPLE Loss | + | |<span class="blue-text">EXAMPLE:</span> Loss |
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
chr7:1- 159,335,973 [hg38] | chr7:1- 159,335,973 [hg38] | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
chr7 | chr7 | ||
| Line 210: | Line 227: | ||
|Yes | |Yes | ||
|No | |No | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). | Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). | ||
|- | |- | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
8 | 8 | ||
| − | |EXAMPLE Gain | + | |<span class="blue-text">EXAMPLE:</span> Gain |
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
chr8:1-145,138,636 [hg38] | chr8:1-145,138,636 [hg38] | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
chr8 | chr8 | ||
| Line 227: | Line 244: | ||
|No | |No | ||
|No | |No | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
Common recurrent secondary finding for t(8;21) (add reference). | Common recurrent secondary finding for t(8;21) (add reference). | ||
| Line 274: | Line 291: | ||
==Characteristic Chromosomal Patterns== | ==Characteristic Chromosomal Patterns== | ||
| − | Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span> | + | Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.'')</span> |
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 284: | Line 301: | ||
!Notes | !Notes | ||
|- | |- | ||
| − | |EXAMPLE | + | |<span class="blue-text">EXAMPLE:</span> |
Co-deletion of 1p and 18q | Co-deletion of 1p and 18q | ||
| Line 290: | Line 307: | ||
|No | |No | ||
|No | |No | ||
| − | |EXAMPLE: | + | |<span class="blue-text">EXAMPLE:</span> |
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). | See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). | ||
| Line 296: | Line 313: | ||
==Gene Mutations (SNV / INDEL)== | ==Gene Mutations (SNV / INDEL)== | ||
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable | + | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.'') </span> |
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 306: | Line 323: | ||
!Notes | !Notes | ||
|- | |- | ||
| − | |EXAMPLE: TP53; Variable LOF mutations | + | |<span class="blue-text">EXAMPLE:</span> TP53; Variable LOF mutations |
| − | EXAMPLE: | + | <span class="blue-text">EXAMPLE:</span> |
EGFR; Exon 20 mutations | EGFR; Exon 20 mutations | ||
| − | EXAMPLE: BRAF; Activating mutations | + | <span class="blue-text">EXAMPLE:</span> BRAF; Activating mutations |
| − | |EXAMPLE: TSG | + | |<span class="blue-text">EXAMPLE:</span> TSG |
| − | |EXAMPLE: 20% (COSMIC) | + | |<span class="blue-text">EXAMPLE:</span> 20% (COSMIC) |
| − | EXAMPLE: 30% (add Reference) | + | <span class="blue-text">EXAMPLE:</span> 30% (add Reference) |
| − | |EXAMPLE: IDH1 R123H | + | |<span class="blue-text">EXAMPLE:</span> IDH1 R123H |
| − | |EXAMPLE: EGFR amplification | + | |<span class="blue-text">EXAMPLE:</span> EGFR amplification |
| | | | ||
| | | | ||
| | | | ||
| − | |EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference). | + | |<span class="blue-text">EXAMPLE:</span> Excludes hairy cell leukemia (HCL) (add reference). |
<br /> | <br /> | ||
|} | |} | ||
| Line 418: | Line 435: | ||
==Genes and Main Pathways Involved== | ==Genes and Main Pathways Involved== | ||
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span> | + | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span> |
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | ||
|- | |- | ||
| − | |EXAMPLE: BRAF and MAP2K1; Activating mutations | + | |<span class="blue-text">EXAMPLE:</span> BRAF and MAP2K1; Activating mutations |
| − | |EXAMPLE: MAPK signaling | + | |<span class="blue-text">EXAMPLE:</span> MAPK signaling |
| − | |EXAMPLE: Increased cell growth and proliferation | + | |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation |
|- | |- | ||
| − | |EXAMPLE: CDKN2A; Inactivating mutations | + | |<span class="blue-text">EXAMPLE:</span> CDKN2A; Inactivating mutations |
| − | |EXAMPLE: Cell cycle regulation | + | |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation |
| − | |EXAMPLE: Unregulated cell division | + | |<span class="blue-text">EXAMPLE:</span> Unregulated cell division |
|- | |- | ||
| − | |EXAMPLE: KMT2C and ARID1A; Inactivating mutations | + | |<span class="blue-text">EXAMPLE:</span> KMT2C and ARID1A; Inactivating mutations |
| − | |EXAMPLE: Histone modification, chromatin remodeling | + | |<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling |
| − | |EXAMPLE: Abnormal gene expression program | + | |<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program |
|} | |} | ||
Latest revision as of 17:31, 6 September 2024
Haematolymphoid Tumours (WHO Classification, 5th ed.)
 | This page is under construction |
editContent Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition ClassificationThis page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Burkitt Lymphoma.
(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)
Primary Author(s)*
Becky Leung, MBBS (Hons), BSc, Pathology Queensland
WHO Classification of Disease
| Structure | Disease |
|---|---|
| Book | Haematolymphoid Tumours (5th ed.) |
| Category | B-cell lymphoid proliferations and lymphomas |
| Family | Mature B-cell neoplasms |
| Type | N/A |
| Subtype(s) | Burkitt lymphoma |
Definition / Description of Disease
Put your text here (Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories, diagnostic criteria if applicable, and differential diagnosis if applicable. Other classifications can be referenced for comparison.)
Synonyms / Terminology
Put your text here (Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.)
Epidemiology / Prevalence
Put your text here
Clinical Features
Put your text here and fill in the table (Instruction: Can include references in the table. Do not delete table.)
| Signs and Symptoms | EXAMPLE: Asymptomatic (incidental finding on complete blood counts)
EXAMPLE: B-symptoms (weight loss, fever, night sweats) EXAMPLE: Fatigue EXAMPLE: Lymphadenopathy (uncommon) |
| Laboratory Findings | EXAMPLE: Cytopenias
EXAMPLE: Lymphocytosis (low level) |
editv4:Clinical FeaturesThe content below was from the old template. Please incorporate above.Patients often present with bulky disease and high tumour burden, showing rapid clinical progression. The typically involved anatomical sites are different for the three subtypes. At presentation, 30% have localised (stage I or II) disease and 70% have advanced (stage III or IV) disease, according to the revised international paediatric non-Hodgkin lymphoma staging system.
Tumour masses can compress and/or infiltrate adjacent tissues.
Due to the high chemosensitivity of the tumour, treatment of Burkitt Lymphoma with chemotherapy can lead to rapid tumour cell death and an acute tumour lysis syndrome secondary to this.
Sites of Involvement
Extra-nodal sites most often involved:
- Commonly involved sites: jaw and facial bones, ileocaecal region, omentum, gonads, kidneys, long bones, thyroid, salivary glands and breasts
- Jaws and other facial bones are the site of presentation in 50-70% of cases of endemic Burkitt lymphoma
- Central nervous system
- The ileocaecal region is the most frequently involved site in sporadic Burkitt lymphoma
Lymph node and bone marrow involvement less common but:
- Frequent in immunodeficiency-associated Burkitt lymphoma
- Presentation with lymphadenopathy is more common in adults than children
- Waldeyer ring or mediastinal involvement is rare
Burkitt leukaemia variant
- Leukaemic phase can be observed in patients with bulky disease
- Only rare cases present purely as leukaemia with peripheral blood and bone marrow involvement, this more typically seen in males
- Tends to involve the CNS at diagnosis or early in the disease course
- Uncommon in endemic Burkitt lymphoma
Morphologic Features
Tissue specimens
- Diffuse monotonous effacement of normal architecture by sheets of medium-sized lymphoid cells
- At low power, tissue can have interspersed areas of coagulative necrosis or haemorrhage
- High proliferation rate with a high rate of spontaneous apoptosis and many mitotic figures
- A starry sky pattern is usually present, this refers to the presence of numerous tingible body macrophages that have phagocytosed apoptotic tumour cells. These macrophages have abundant clear cytoplasm and are dispersed throughout the basophilic tumour cells.
Nucleus
- Round with finely clumped chromatin and multiple basophilic paracentral nucleoli
Cytoplasm
- Deeply basophillic with lipid vacuoles
Variations
- Some cases have a florid granulomatous reaction, which typically is associated with limited stage disease and good prognosis
- Some cases can exhibit plasmacytoid differentiation with eccentric basophilic cytoplasm and a single central nucleolus (particularly with immundeficiency-associated Burkitt lymphoma)
Immunophenotype
Burkitt lymphoma is a germinal centre B-cell derived malignancy. Aberrant immunophenotypes (CD5 positive, CD10 negative, BCL2 weak) may be seen particularly in the Burkitt lymphoma of older patients. Burkitt leukaemia shows a similar immunophenotype to Burkitt lymphoma, in rare cases TdT and possibly CD34 expression, or loss of CD20 and surface immunoglobulin is seen.
| Finding | Marker |
|---|---|
| Positive (near-universal) | MYC (strong) |
| Positive (typically) | B cell antigens: CD19, CD20, CD22, CD79a, PAX5
Germinal centre markers: CD10, BCL6 surface IgM (moderate-strong) with light chain restriction Ki67 typically high ~100% |
| Positive (frequent) | CD38, CD77, CD43 |
| Positive (paediatric) | TCL1 |
| Negative (usually) | CD5, CD23, CD138, BCL2, TdT |
Chromosomal Rearrangements (Gene Fusions)
Put your text here and fill in the table
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
| EXAMPLE: t(9;22)(q34;q11.2) | EXAMPLE: 3'ABL1 / 5'BCR | EXAMPLE: der(22) | EXAMPLE: 20% (COSMIC)
EXAMPLE: 30% (add reference) |
Yes | No | Yes | EXAMPLE:
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). |
editv4:Chromosomal Rearrangements (Gene Fusions)The content below was from the old template. Please incorporate above.The development of Burkitt lymphoma is dependent on the constitutive expression of the MYC proto-oncogene. The MYC encoded protein is a transcriptional regulator, controlling target genes involved in cell cycle regulation, metabolism and apoptosis. Dysregulation of MYC expression occurs due to juxtaposition of regulatory elements of the immunoglobulin loci, usually IGH, but also IGL or IGK. Overexpression of MYC correlates with increased cell survival. The different Burkitt lymphoma subtypes harbour diverse MYC and IGH locus breakpoints. In endemic Burkitt lymphoma, MYC usually breaks several hundred kilobases further upstream and IG usually breaks in the VDJ region. In contrast, most sporadic and immunodeficiency-associated Burkitt lymphoma have chromosomal breakpoints within exon 1 and the first intron of MYC and at the class switch region of IG[1]. Although fluorescence in situ hydribisation (FISH) methods are well established in most pathology laboratories, no single probe set is able to cover all MYC breakpoints. In particular, distant breakpoints, complex rearrangements and cryptic insertions may be overlooked[2]. Hence, multiple FISH probe sets are required for comprehensive detection of clinically relevant MYC gene rearrangements.
A translocation involving MYC cannot be detected by FISH or classical cytogenetics in a small percentage of cases (less than 5%). This may be due to technical issues, such as a very small excision of MYC and insertion of the gene onto the IG loci, or a breakpoint localised outside the regions covered by the utilised FISH probes[3]. Mechanisms other then translocation that similarly lead to MYC overexpression have also been implicated in the development of Burkitt lymphoma[4]. Investigation for these should be considered in the presence of a consistent clinical and laboratory phenotype, where fusions are not detected.
Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence t(8;14)(q24;q32) 5'IGH / 3'MYC der(14) 85% t(8;22)(q24;q11) 5'MYC / 3'IGL der(8) 10% t(2;8)(p12;q24) 5'MYC / 3'IGK der(8) 5%
editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).Please incorporate this section into the relevant tables found in:
- Chromosomal Rearrangements (Gene Fusions)
- Individual Region Genomic Gain/Loss/LOH
- Characteristic Chromosomal Patterns
- Gene Mutations (SNV/INDEL)
Deciphering the genomic landscape of Burkitt lymphoma provides additional molecular targets for new treatment regimens. Burkitt lymphoma is often curable using intensive chemotherapy treatments. However, these regimens may not be well tolerated by older individuals and further treatment options are required for those who exhibit refractory or relapsed disease.
Considerations are for inhibitors of PI3K signaling and downstream pathways, and inhibiting cyclin dependent kinase 4/6 to block cyclin D3 mediated cell cycle progression.
Individual Region Genomic Gain / Loss / LOH
Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.)
| Chr # | Gain / Loss / Amp / LOH | Minimal Region Genomic Coordinates [Genome Build] | Minimal Region Cytoband | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
| EXAMPLE:
7 |
EXAMPLE: Loss | EXAMPLE:
chr7:1- 159,335,973 [hg38] |
EXAMPLE:
chr7 |
Yes | Yes | No | EXAMPLE:
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). |
| EXAMPLE:
8 |
EXAMPLE: Gain | EXAMPLE:
chr8:1-145,138,636 [hg38] |
EXAMPLE:
chr8 |
No | No | No | EXAMPLE:
Common recurrent secondary finding for t(8;21) (add reference). |
editv4:Genomic Gain/Loss/LOHThe content below was from the old template. Please incorporate above.Most often, Burkitt lymphoma is associated with a simple karyotype. However additional chromosomal abnormalities may also occur and play a role in disease progression, see the table below for the more commonly implicated cytogenetic abnormalities.
In the context of a Burkitt lymphoma-like phenotype and/or Burkitt-like morphological appearance, the diagnosis of 'Burkitt-like lymphoma with 11q aberration' should be considered. This provisional WHO entity lacks a detectable MYC rearrangement, but shows alterations of 11q. These 11q alterations typically include proximal gains (eg 11q23.2-23.3), and telomeric losses (eg 11q24.1-ter). MicroRNA and gene expression profiling patterns are consistent with Burkitt lymphoma. Other common karyotypic features of this condition include a complex karyotype, and lack of the 1q loss typical of Burkitt lymphoma.
Chromosome Number Gain/Loss/Amp/LOH Region 1q Gain 21-25 6q Loss 11-14 7 Gain 8 Gain 12 Gain 13q Loss 32-34 17p Loss 18 Gain
Characteristic Chromosomal Patterns
Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.)
| Chromosomal Pattern | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|
| EXAMPLE:
Co-deletion of 1p and 18q |
Yes | No | No | EXAMPLE:
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). |
Gene Mutations (SNV / INDEL)
Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.)
| Gene; Genetic Alteration | Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) | Prevalence (COSMIC / TCGA / Other) | Concomitant Mutations | Mutually Exclusive Mutations | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|---|
| EXAMPLE: TP53; Variable LOF mutations
EXAMPLE: EGFR; Exon 20 mutations EXAMPLE: BRAF; Activating mutations |
EXAMPLE: TSG | EXAMPLE: 20% (COSMIC)
EXAMPLE: 30% (add Reference) |
EXAMPLE: IDH1 R123H | EXAMPLE: EGFR amplification | EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).
|
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
editv4:Gene Mutations (SNV/INDEL)The content below was from the old template. Please incorporate above.
Gene Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence (COSMIC/TCGA/Other) MYC Oncogene GOF 67% ID3[5] Tumour suppressor LOF 34% DDX3X[6] Tumour suppressor LOF 34% BCL6[7] Oncogene GOF 25% BCL7A[8] Oncogene GOF 24% FBXO11[9] Tumour suppressor LOF 23% FOXO1[10] Oncogene GOF 23% SMARCA4[11] Tumour suppressor LOF 23% ARID1A[12] Tumour suppressor LOF 18% TP53[13] Tumour suppressor LOF 17% CTCF[14] Tumour suppressor LOF 16% CREBBP[15] Tumour suppressor LOF 15% TCL1A[16] Oncogene GOF 15% BCR[17] Oncogene GOF 15% TCF3[18] Oncogene GOF 14% CCND3[19] Oncogene GOF 14%
Epigenomic Alterations
Put your text here
Genes and Main Pathways Involved
Put your text here and fill in the table (Instructions: Can include references in the table. Do not delete table.)
| Gene; Genetic Alteration | Pathway | Pathophysiologic Outcome |
|---|---|---|
| EXAMPLE: BRAF and MAP2K1; Activating mutations | EXAMPLE: MAPK signaling | EXAMPLE: Increased cell growth and proliferation |
| EXAMPLE: CDKN2A; Inactivating mutations | EXAMPLE: Cell cycle regulation | EXAMPLE: Unregulated cell division |
| EXAMPLE: KMT2C and ARID1A; Inactivating mutations | EXAMPLE: Histone modification, chromatin remodeling | EXAMPLE: Abnormal gene expression program |
editv4:Genes and Main Pathways InvolvedThe content below was from the old template. Please incorporate above.MYC is the most commonly mutated gene in Burkitt lymphoma, such variants lead to constitutive expression of MYC, which drives cell survival. Aberrant somatic hypermutation is understood to be the major cause of MYC breakpoint formation and the presence of hypermutation in tandem with MYC rearrangement may be detectable if using sequencing methodologies.
Localised TP53 inactivating mutations or chromosomal deletions involving TP53 are also common in Burkitt lymphoma, and cause abrogation of TP53-dependent apoptotic pathways. Loss of TP53 function through the aforementioned means, or dysregulation due to the mutation of TP53 regulatory elements, is believed to be key to the development of Burkitt lymphoma[20].
TCF3 or ID3 mutations are seen in approximately 70% of sporadic Burkitt lymphoma. The normal function of transcription factor E2A (encoded by TCF3) is regulation of the differentiation of B-cells in the germinal centre. Mutations in TCF3 leads to reduced affinity for its negative regulator, ID3, promoting constitutive activity. TCF3 promotes B-cell receptor signaling in Burkitt lymphoma, which enhances survival via the PI3 kinase pathway. TCF3 also transactivates CCND3 which encodes cyclin D3 expression, promoting cell cycle progression and proliferation[21].
Mutations overall, and in particular in TCF3 and ID3, are less common in endemic Burkitt lymphoma when compared to sporadic cases. It is postulated that this additional mutational burden may take the place of EBV in sporadic Burkitt lymphomagenesis, given that either mechanism can lead to the activation of B-cell receptor signaling.
The gene expression and micro-RNA expression profiles of Burkitt lymphoma are different from other lymphomas. The expression profiles of endemic and sporadic BL are also slightly different to each other. There may be grey zones where Burkitt lymphoma is difficult to distinguish from diffuse large B-cell lymphoma based on gene expression, hence expression should not be used as an independent diagnostic tool[22].
Genetic Diagnostic Testing Methods
Put your text here
Familial Forms
The X-linked lymphoproliferative syndrome 'Duncan disease', is associated with SH2D1A mutations. Individuals with this condition are at greatly increased risk of developing Burkitt lymphoma.
Additional Information
Put your text here
Links
HAEM5:High grade B-cell lymphoma with 11q aberrations
References
(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)
- ↑ Neri, A.; et al. (1988-04-01). "Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma". Proceedings of the National Academy of Sciences. 85 (8): 2748–2752. doi:10.1073/pnas.85.8.2748. ISSN 0027-8424.
- ↑ Muñoz-Mármol, Ana M; et al. (2013-09). "MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection". Histopathology. 63 (3): 418–424. doi:10.1111/his.12178. Check date values in:
|date=(help) - ↑ De Falco, Giulia; et al. (2015-10-09). "Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation". BMC Cancer. 15 (1). doi:10.1186/s12885-015-1661-7. ISSN 1471-2407.
- ↑ Leucci, E; et al. (2008-09-18). "MYC translocation‐negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation". The Journal of Pathology. 216 (4): 440–450. doi:10.1002/path.2410. ISSN 0022-3417. line feed character in
|title=at position 4 (help) - ↑ Richter, Julia; et al. (2012-12). "Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing". Nature Genetics. 44 (12): 1316–1320. doi:10.1038/ng.2469. ISSN 1546-1718. PMID 23143595. Check date values in:
|date=(help) - ↑ Mo, Jie; et al. (2021-02-24). "DDX3X: structure, physiologic functions and cancer". Molecular Cancer. 20 (1). doi:10.1186/s12943-021-01325-7. ISSN 1476-4598.
- ↑ Kl, Bunting; et al. (2013 Jun). "New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes". doi:10.1016/j.coi.2013.05.003. PMC 4075446. PMID 23725655. Check date values in:
|date=(help)CS1 maint: PMC format (link) - ↑ Zani, V. J.; et al. (1996-04-15). "Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon". Blood. 87 (8): 3124–3134. ISSN 0006-4971. PMID 8605326.
- ↑ Pighi, Chiara; et al. (2015-12-03). "FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma". Blood. 126 (23): 3673–3673. doi:10.1182/blood.v126.23.3673.3673. ISSN 0006-4971.
- ↑ Zhou, Peixun; et al. (2019-07-23). "Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif". Blood Advances. 3 (14): 2118–2127. doi:10.1182/bloodadvances.2018029546. ISSN 2473-9537. PMC 6650741. PMID 31300419.
- ↑ Love, Cassandra; et al. (2012-12). "The genetic landscape of mutations in Burkitt lymphoma". Nature Genetics. 44 (12): 1321–1325. doi:10.1038/ng.2468. ISSN 1546-1718. PMC 3674561. PMID 23143597. Check date values in:
|date=(help) - ↑ Love, Cassandra; et al. (2012-12). "The genetic landscape of mutations in Burkitt lymphoma". Nature Genetics. 44 (12): 1321–1325. doi:10.1038/ng.2468. ISSN 1546-1718. PMC 3674561. PMID 23143597. Check date values in:
|date=(help) - ↑ Shannon-Lowe, Claire; et al. (2017-10-19). "Epstein-Barr virus-associated lymphomas". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 372 (1732). doi:10.1098/rstb.2016.0271. ISSN 1471-2970. PMC 5597738. PMID 28893938.
- ↑ Chau, Charles M.; et al. (2006-06-15). "Regulation of Epstein-Barr Virus Latency Type by the Chromatin Boundary Factor CTCF". Journal of Virology. 80 (12): 5723–5732. doi:10.1128/JVI.00025-06. ISSN 0022-538X. PMC 1472585. PMID 16731911.CS1 maint: PMC format (link)
- ↑ Love, Cassandra; et al. (2012-12). "The genetic landscape of mutations in Burkitt lymphoma". Nature Genetics. 44 (12): 1321–1325. doi:10.1038/ng.2468. ISSN 1546-1718. PMC 3674561. PMID 23143597. Check date values in:
|date=(help) - ↑ Aggarwal, Mohit; et al. (2008-09-26). "TCL1A expression delineates biological and clinical variability in B-cell lymphoma". Modern Pathology. 22 (2): 206–215. doi:10.1038/modpathol.2008.148. ISSN 0893-3952.
- ↑ Küppers, Ralf (2005-04). "Mechanisms of B-cell lymphoma pathogenesis". Nature Reviews Cancer. 5 (4): 251–262. doi:10.1038/nrc1589. ISSN 1474-175X. Check date values in:
|date=(help) - ↑ Schmitz, Roland; et al. (2012-10-04). "Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics". Nature. 490 (7418): 116–120. doi:10.1038/nature11378. ISSN 1476-4687. PMC 3609867. PMID 22885699.
- ↑ Schmitz, Roland; et al. (2012-10-04). "Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics". Nature. 490 (7418): 116–120. doi:10.1038/nature11378. ISSN 1476-4687. PMC 3609867. PMID 22885699.
- ↑ Shannon-Lowe, Claire; et al. (2017-10-19). "Epstein-Barr virus-associated lymphomas". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 372 (1732). doi:10.1098/rstb.2016.0271. ISSN 1471-2970. PMC 5597738. PMID 28893938.
- ↑ Schmitz, Roland; et al. (2012-10-04). "Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics". Nature. 490 (7418): 116–120. doi:10.1038/nature11378. ISSN 1476-4687. PMC 3609867. PMID 22885699.
- ↑ Shannon-Lowe, Claire; et al. (2017-10-19). "Epstein-Barr virus-associated lymphomas". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 372 (1732). doi:10.1098/rstb.2016.0271. ISSN 1471-2970. PMC 5597738. PMID 28893938.
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
*Citation of this Page: “Burkitt lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 09/6/2024, https://ccga.io/index.php/HAEM5:Burkitt_lymphoma.
Other Sections
Cancer Sub-Classification/Subtype
Burkitt lymphoma
Definition/Description of Disease
Burkitt lymphoma is a clinically aggressive but curable lymphoma with three aetiologically distinct subtypes, these being endemic, sporadic and immunodeficiency-associated Burkitt lymphoma. Infection with Epstein-Bar virus (EBV), also known as human herpesvirus 4, is seen all three subtypes, but is most strongly associated with endemic Burkitt Lymphoma. Detectable EBV infection is not essential for diagnosis, and may not be the cause in all cases; the frequency of EBV infection varies according to the epidemiological subtype of Burkitt lymphoma. The clinical presentation often involves extra-nodal sites but the disease can also present as an acute leukaemia.
Synonyms/Terminology
Burkitt cell leukaemia
Obsolete terms
- Burkitt tumour
- Malignant lymphoma, undifferentiated, Burkitt type
- Malignant lymphoma, small non-cleaved, Burkitt type
Epidemiology/Prevalence
Endemic Burkitt lymphoma
- Highly associated with Epstein-Barr virus (EBV genome present in >95% of neoplastic cells) and Plasmodium falciparum infection
- Occurs in equatorial Africa and Papua New Guinea, with a distribution that overlaps with regions endemic for malaria
- Demographics: peak incidence among children aged 4-7 years
- The incidence is higher in males than females, at a ratio of 2:1
Sporadic Burkitt lymphoma
- EBV detected in 20-30% of cases, proportion of EBV positive cases appears to be much higher in adults than in children
- Occurs worldwide
- Western Europe and USA: low incidence, accounting for only 1-2% of all lymphomas overall (30-50% of all childhood lymphomas)
- South America and northern Africa: incidence between that of sporadic Burkitt lymphoma in developed countries and endemic Burkitt lymphoma
- Demographics: peak incidence among children and young adults (median age 30 years, with separate incidence peak in elderly patients)
- M:F 2-3:1
Immunodeficiency-associated Burkitt lymphoma
- EBV detected in 25-40% of cases
- Associated with HIV infection (most commonly) and other forms of immunosuppression
- Occurs early in the course of HIV infection, when CD4+ T cell counts are still high
- Increased risk of developing Burkitt lymphoma has persisted across the pre-and post-HAART eras